Журнал "Гастроэнтерология" Том 56, №3, 2022
Вернуться к номеру
Fatty acid content depending on the duration of inflammatory bowel disease
Авторы: M.V. Stoikevich, V.A. Karachynova, I.A. Klenina, O.P. Petishko
SI “Institute of Gastroenterology of the NAMS of Ukraine”, Dnipro, Ukraine
Рубрики: Гастроэнтерология
Разделы: Медицинские форумы
Версия для печати
The aim of the article: аnalysis of saturated fatty acids (SFAs) content in serum of patients with different duration of inflammatory bowel disease (IBD).
Materials and methods. 37 patients with IBD were included in the study, among which there were 27 with non-specific ulcerative colitis, and 10 patients with Crohn’s disease. The average age was (38.5 ± 2.1) years. 3 Groups were formed depending on the duration of the disease: І — ≤ 5 years (n = 21), ІІ — > 5 — ≤ 10 years (n = 10), ІІІ — > 10 years (n = 6). There were 16 healthy people in the control group. Chromatographic examination in the blood serum short-, medium- and long-chain SFAs (SC SFAs, MC SFAs and LC SFAs, respectively) was performed by the gas chromatograph “Chromatek-Crystal 5000”. The content of SFAs was presented in μg/μl. The median (Me), lower (25 %)/upper (75 %) quartiles was chosen to describe the data. The parameters were compared by Mann-Whitney U-criterion.
Results. The total content of SFAs in the blood serum of patients of group I increased significantly in 7.1 fold (р < 0.001) to 25.5 (10.9; 30.8), in group II — in 4.8 fold (р < 0.001) to 17.4 (10.4; 25.1) and in group III — in 3.6 fold (р < 0.001) to 12.9 (10.7; 20.8) relative to control (3.56 (1.7; 4.7)). However, with the increase of IBD duration, the total content of SFAs was gradually decreasing (r = –0,344, р < 0.05), and already in group II it was 2 fold lower than in group I (p > 0,05). The content of SC SFAs (C4:0–C8:0) significantly increased in groups I, II and III in 4 fold (p < 0.001) to 11.6 (9.02; 24,3), in 4.2 fold (p < 0,001) to 12.1 (5.8; 18.6) and in 2.4 fold (p < 0.05) to 6.9 (6.1; 7.9) respectively, compared to control (2.9 (0.7; 4.4)). The content of SC SFAs in group III was significantly reduced in 1.7 fold (p < 0.05), compared to group I. The content of MC SFAs (C10:0–C14:0) changed similarly to the content of SC SFAs: increased in 18 fold (p < 0.001) to 0.11 (0.07; 0.15), in 13 fold (p < 0.001) to 0.09 (0.06; 0.13) and in 12 fold (p < 0.001) to 0.07 (0.04; 0.10) for three groups, respectively, compared to control (0.006 (0.005; 0.03). There was a tendency for decrease of MC SFAs in 1.5 fold in group III (p > 0.05), as compared to group I. The content of LC SFAs (C15:0– C21:0) significantly increased in all three groups, but without significant intergroup difference: in 12.5 fold (p < 0.001) to 6.0 (2.1; 9.9), in 10 fold (p < 0.001) to 5.0 (3.5; 6.4) and in 12 fold (p < 0.001) to 5.8 (3.5; 14.4) respectively, relative to control (0.48 (0.12; 0.89)).
Conclusion. It was shown that the quantitative content of SFAs in the blood serum of patients with IBD was related to the duration of the disease. SC SFAs have anti-inflammatory properties, influence cell proliferation and contribute to the maintenance of epithelial homeostasis, while LC SFAs are precursors of pro- and anti-inflammatory molecules, influence pro- and anti-inflammatory mediators, so the results of research in this direction can be used to correct treatment of patients with IBD.